Abstract
A double-blind study was carried out to investigate the possibility of therapeutic effect of levamisole on recurrent progenital herpes. One hundred and nine patients, including 53 females, entered the study, but only 75 completed. Levamisole, 50 mg three times daily for 3 days, was started at the first sign of recurrence. The study period consisted of 6 visits or 12 months, whichever came first. No statistical differences were observed between levamisole and placebo groups when comparing the duration of the lesion and the degree of pain, although less pain was observed among those on levamisole. The interval between attacks was increasingly prolonged in the levamisole-treated group, and reached a significant level at the sixth visit. However, analysis on the basis of mean cumulative number of days between attacks showed no significant differences throughout the study period. Because of occasional neutropenia and generalized urticaria, and because of the absence of clear-cut clinical improvement of statistical significance, levamisole was considered of limited benefit to patients with recurrent genital herpes infection.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Kint A., Verlinden L. Letter: Levamisole for recurrent herpes labialis. N Engl J Med. 1974 Aug 8;291(6):308–308. doi: 10.1056/NEJM197408082910614. [DOI] [PubMed] [Google Scholar]
- O'Reilly R. J., Chibbaro A., Anger E., Lopez C. Cell-mediated immune responses in patients with recurrent Herpes Simplex infections. II. Infection-associated deficiency of lymphokine production in patients with recurrent herpes labialis or herpes progenitalis. J Immunol. 1977 Mar;118(3):1095–1102. [PubMed] [Google Scholar]
- O'Reilly R. J., Chibbaro A., Wilmot R., Lopez C. Correlation of clinical and virus-specific immune responses following levamisole therapy of recurrent herpes progenitalis. Ann N Y Acad Sci. 1977 Mar 4;284:161–170. doi: 10.1111/j.1749-6632.1977.tb21947.x. [DOI] [PubMed] [Google Scholar]
- Ramot B., Biniaminov M., Shoham C., Rosenthal E. Effect of levamisole on E-rosette-forming cells in vivo and in vitro in Hodgkin's disease. N Engl J Med. 1976 Apr 8;294(15):809–811. doi: 10.1056/NEJM197604082941504. [DOI] [PubMed] [Google Scholar]
- Russell A. S. Cell-mediated immunity to herpes simplex virus in man. J Infect Dis. 1974 Feb;129(2):142–146. doi: 10.1093/infdis/129.2.142. [DOI] [PubMed] [Google Scholar]
- Steele R. W., Vincent M. M., Hensen S. A., Fuccillo D. A., Chapa I. A., Canales L. Cellular immune responses to Herpes simplex virus type 1 in recurrent herpes labialis: in vitro blastogenesis and cytotoxicity to infected cell line. J Infect Dis. 1975 May;131(5):528–534. doi: 10.1093/infdis/131.5.528. [DOI] [PubMed] [Google Scholar]
- Symoens J., Brugmans J. Letter: Treatment of recurrent aphthous stomatitis and herpes with levamisole. Br Med J. 1974 Dec 7;4(5944):592–592. doi: 10.1136/bmj.4.5944.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Symoens J., Rosenthal M. Levamisole in the modulation of the immune response: the current experimental and clinical state. J Reticuloendothel Soc. 1977 Mar;21(3):175–221. [PubMed] [Google Scholar]